MedTrace Logo

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

NCT04756531 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-10-15

Study results available
· View outcomes & findings →

Summary

A Phase 1, double blind, sponsor open, single and multiple ascending dose study to evaluate safety, tolerability and pharmacokinetics of PF-07321332 in healthy participants.

Conditions

  • Healthy Participants

Interventions

DRUG

PF-07321332 Dose 1

PF-07321332 Dose 1 or Placebo

DRUG

PF-07321332 Dose 2

PF-07321332 Dose 2 or Placebo

DRUG

PF-07321332 Dose 3

PF-07321332 Dose 3 or Placebo

DRUG

PF-07321332 Dose 4

PF-07321332 Dose 4 or Placebo

DRUG

PF-07321332 Dose 5

PF-07321332 Dose 5 or Placebo

DRUG

PF-07321332 Dose 4 or Placebo (Fed)

PF-07321332 Dose 5 or Placebo with high fat meal

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-11
Primary Completion
2021-09-01
Completion
2021-09-01
FDA Drug
Yes

Countries

  • United States
  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04756531 on ClinicalTrials.gov